Fundz

Aqualung Therapeutics, An Immunotherapeutics Biotech Company, Receives First $1.5M Toward Series A Preferred Capital Raise; Will Present At 2023 Annual Biotech Showcase

PRIVATEDec 05, 2022

Amount Raised

$1.5 Million

Round Type

Series A

TucsonBiotechnologyHealth CareTherapeutics

Description

TUCSON, AZ / December 5, 2022 / Aqualung Therapeutics, an early stage immunotherapeutics company with an anti-inflammatory and anti-fibrotic therapeutic platform for life-threatening unchecked inflammation/fibrosis, will be presenting at the annual Biotech Showcase in San Francisco in conjunction with the JP Morgan Healthcare conference, Tuesday, January 10th, 9:45am-10:15am pacific time, Hilton Hotel, Franciscan A, Ballroom Level.

Quick answer

Aqualung Therapeutics Corp. raised $1.5 Million in a Series A round, dated December 5, 2022. Aqualung Therapeutics Corp. is based in Tucson, Arizona, United States.

How much did Aqualung Therapeutics Corp. raise?
Aqualung Therapeutics Corp. raised $1.5 Million in a Series A round on December 5, 2022.
What does Aqualung Therapeutics Corp. do?
Aqualung is an early-stage biotech immunotherapeutics company which has developed an anti-inflammatory therapeutic platform for patients with life-threatening unchecked inflammation.
Where is Aqualung Therapeutics Corp. based and how big is it?
Aqualung Therapeutics Corp. is based in Tucson, Arizona, United States.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Aqualung Therapeutics Corp. that raised within 45 days of this round, from Fundz verified event records.

  • Repare Therapeutics raised $1.5M (Seed) on January 19, 2023.
  • Diamante Srl raised an undisclosed amount (Seed) on January 17, 2023.
  • MPC Therapeutics raised an undisclosed amount (Seed) on January 11, 2023.
  • Liquidia raised an undisclosed amount (Debt Financing) on January 9, 2023.
  • Inotrem raised an undisclosed amount (Funding Round) on January 9, 2023.
  • Synthekine raised $100M (Series C) on January 6, 2023.

Who to call at Aqualung Therapeutics Corp., and when

A new round usually means Aqualung Therapeutics Corp. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Aqualung Therapeutics Corp. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Aqualung Therapeutics Corp., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Aqualung Therapeutics Corp.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Aqualung Therapeutics Corp.

Location

1790 EAST RIVER ROAD

Tucson, Arizona, United States

About

Aqualung is an early-stage biotech immunotherapeutics company which has developed an anti-inflammatory therapeutic platform for patients with life-threatening unchecked inflammation. Founded in 2016 and led by a physician-scientist, Aqualung's science-driven approaches led to the identification of nicotinamide phosphoribosyltransferase (NAMPT) as a major contributor to the severity of potentially fatal inflammatory diseases. Aqualung Therapeutics has developed eNamptorTM, a Next Gen platform comprised of: i) the humanized ALT 100 mAb, an eNAMPT-neutralizing monoclonal antibody; ii) eNAMPT-Plex, a plasma-based biomarker panel comprised of cytokines and eNAMPT, which predicts ARDS mortality; and iii) NAMPT-Gene, a genotyping assay that identifies individuals genetic variants that predispose to ARDS risk and death. In addition to ARDS and ventilator-induced lung injury, the pipeline of ALT-100 mAb indications currently includes radiation-induced injuries, intrauterine infections during pregnancy (chorioamnionitis), prostate cancer, pulmonary hypertension, autoimmune disorders (IBD, SLE) and both pulmonary and hepatic fibrosis (NASH). Each of these potentially fatal inflammatory conditions exhibits significant unmet medical needs for therapeutics to reduce morbidity and mortality. For additional information about the company, please visit www.aqualungtherapeutics.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Aqualung Therapeutics Corp. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Aqualung Therapeutics Corp.'s next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Aqualung Therapeutics Corp. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.